• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pfizer Inc.

EpiPen shortage in Canada to last until March

January 19, 2018 By Sarah Faulkner

EpiPen

Pfizer Canada (NYSE:PFE) has warned Health Canada that there is a shortage of 0.3 mg EpiPen auto-injectors due to a manufacturing disruption. The company, which licenses the emergency allergy treatment from Mylan (NSDQ:MYL), reported that the problem should be resolved by March 2. There are no alternative auto-injectors available on the market in Canada for patients at […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Mylan, Pfizer Inc.

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Ocugen

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer Inc., Regeneron, Roche, Shire

United Therapeutics dishes out $210m to settle charity-kickback claims

December 21, 2017 By Sarah Faulkner

Prescription drugs

United Therapeutics (NSDQ:UTHR) has agreed to pay $210 million to squash claims that it used a charity to illegally cover Medicare patients’ out-of-pocket costs in an attempt to boost sales. Drug companies are not allowed to subsidize co-pays for people enrolled in Medicare, but they can donate to independent non-profits that provide co-pay assistance. The settlement […]

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson, Pfizer Inc., United Therapeutics

Kala Pharmaceuticals taps biopharma exec as chief operating officer | Personnel Moves – Nov. 27, 2017

November 27, 2017 By Sarah Faulkner

Kala Pharmaceuticals

Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Biogen Idec, Delcath Systems Inc., Eli Lilly & Co., Gamida Cell, Kala Pharmaceuticals, neurocrinebiosciences, pertinaxpharma, Pfizer Inc.

Startup aims to disrupt asthma, COPD space with digital inhaler

November 8, 2017 By Sarah Faulkner

Pneuma Respiratory device

Formed just two years ago, pharma startup Pneuma Respiratory is developing a digital inhaler that it touts as the first of its kind. The company is looking to bring its technology to the more than 40 million people who suffer from asthma or chronic obstructive pulmonary disease in the U.S. They’re stepping into a highly […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: cree, generalelectric, GlaxoSmithKline plc, Merck, Pfizer Inc., pneumarespiratory, Propeller Health

Pfizer posts Street-beating Q3, raises full-year earnings forecast

October 31, 2017 By Sarah Faulkner

Pfizer

Shares in Pfizer (NYSE:PFE) fell slightly today even though the pharmaceutical giant beat expectations on Wall Street with its third quarter results. The New York-based company posted profits of $2.84 billion, or 47¢ per share, on sales of $13.17 billion, for sales growth of 1% compared with last year’s third quarter results. Adjusted to exclude 1-time […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Pfizer Inc.

Meet 5 companies developing novel drug-delivery devices

October 26, 2017 By Sarah Faulkner

At the 7th annual Partnership Opportunities in Drug Delivery event, presented by The Conference Forum, device companies gathered to tout their drug-delivery technologies and learn from each other’s mistakes and successes. Among them were needle-free injectors, patch pumps, auto-injectors and other novel delivery devices. Moderated by Pfizer‘s (NYSE:PFE) senior director of device strategy, Mathias Romacker, […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Becton Dickinson, Bespak, Enable Injections, Insulet, Pfizer Inc., West Pharmaceutical Services

Awaiting tax reform clarity, Pfizer delays potential M&A

August 1, 2017 By Sarah Faulkner

Pfizer

(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull […]

Filed Under: Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Pfizer Inc.

Trump pushes ‘America First’ policy with pharmaceutical packaging industry

July 21, 2017 By Sarah Faulkner

capitol hill

Donald Trump yesterday revealed an initiative to bring jobs and investment into the U.S. drug packaging industry, spearheaded by Corning Inc. (NYSE:GLW), Merck (NYSE:MRK) and Pfizer (NYSE:PFE). At the ‘Made In America’ event, Trump announced that the companies are making a $500 million investment to create 1,000 jobs at manufacturing facilities in New York, New Jersey and […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: corning, Merck, Pfizer Inc.

FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers

June 23, 2017 By Sarah Faulkner

Oncomine diagnostic test

The FDA said today that it awarded premarket approval to Thermo Fisher Scientific‘s (NYSE:TMO) next-gen sequencing-based test that can simultaneously screen tumor samples for biomarkers associated with 3 approved therapies for non-small cell lung cancer. The company’s Oncomine Dx Target Test evaluates 23 genes associated with non-small cell lung cancer. The tests results could help […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Novartis, Pfizer Inc., thermofisherscientific

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS